Quanterix: Buy Rating Maintained Amidst Challenges and Growth Opportunities

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Quanterix (QTRX – Research Report), reducing the price target to $12.00.

Kyle Mikson CFA has given his Buy rating due to a combination of factors that suggest potential long-term growth for Quanterix despite current challenges. The company reported a modest beat in its first-quarter results for 2025, with total revenue slightly above estimates, indicating resilience in a tough macroeconomic environment. However, Quanterix has lowered its revenue guidance for 2025 due to increased macroeconomic headwinds, such as tariffs and reduced U.S. academic funding, which could impact near-term performance.
Despite these challenges, Mikson sees potential upside from Quanterix’s new product developments, including the early access program for the Simoa One platform and the planned launch of 15 new assays in 2025. These initiatives could help mitigate the adverse effects of the current economic climate. Additionally, the upcoming merger with Akoya Biosciences is viewed as a strategic move that could enhance long-term growth prospects, although its immediate impact remains uncertain. Consequently, Mikson maintains a Buy rating, reflecting confidence in Quanterix’s ability to navigate through the current challenges and capitalize on future opportunities.

QTRX’s price has also changed dramatically for the past six months – from $15.170 to $5.730, which is a -62.23% drop .